

Home Testing for HIV Infection in Resource-Limited Settings

Ishani Ganguli, BA, Ingrid V. Bassett, MD, MPH, Krista L. Dong, MD, and Rochelle P. Walensky, MD, MPH

Corresponding author

Rochelle P. Walensky, MD, MPH
Division of General Medicine, Massachusetts General Hospital,
50 Staniford Street, 9th Floor, Boston, MA 02114, USA.
E-mail: rwalensky@partners.org

Current HIV/AIDS Reports 2009, 6:217–223

Current Medicine Group LLC ISSN 1548-3568

Copyright © 2009 by Current Medicine Group LLC

Among an estimated 33 million individuals who are infected with HIV worldwide, only 10% are aware of their status. HIV testing is the cornerstone to preventing further transmission and to caring for those infected, particularly as access to treatment improves in resource-limited settings. However, efforts to expand testing through facilities-based testing have not achieved adequate testing coverage, prompting efforts to reach more individuals through strategies such as home-based HIV testing. Home testing is showing promising early results in some high-prevalence, resource-limited settings. This article reviews the mechanisms and literature to date of this door-to-door approach.

Introduction

HIV/AIDS remains a massive global pandemic, with an estimated 33 million people infected worldwide in 2007, yet only 10% of these HIV-infected individuals are aware of their status [1,2]. Once a predictably fatal diagnosis, HIV disease has now become a treatable chronic condition [3]. Because favorable clinical outcomes are contingent upon timely treatment, there is new focus on the early identification of HIV-infected individuals, particularly in resource-limited settings where antiretroviral therapy (ART) is increasingly available.

To this end, efforts to scale up HIV testing have included expansion of voluntary counseling and testing (VCT) centers and launching of antenatal testing programs and hospital-based screening initiatives. These efforts are in keeping with 2006 World Health Organization (WHO) guidelines to promote provider-initiated HIV testing in high-prevalence settings [4]. Although VCT centers provide a reliable testing resource, this

approach has elicited concerns about the feasibility of reaching all individuals at risk, as well as associated stigma, inconvenience, and lack of privacy [5,6]. Provider-initiated testing in health care facilities has been relatively well-received and has had considerable success in identifying HIV-infected individuals by capitalizing on existing health care relationships. However, the strategy only reaches a defined subset of the population: those with access to health care. Both strategies are less likely to capture partners and family members of HIV-infected people, as well as lower socioeconomic groups [7•].

These gaps have prompted the development of complementary models of HIV testing that attempt to bypass these shortcomings and target a wider audience by bringing diagnostic tools to individuals' homes; home-based HIV testing shows promising early results in resource-limited settings. In this review, we discuss home-based HIV testing in such settings, including the types of tests used, demographic populations that are reached by this method, effectiveness compared with other testing strategies, and important next steps in optimizing this approach.

Overview of HIV Diagnostics United States

In the United States, the first HIV diagnostic test was approved by the US Food and Drug Administration (FDA) in 1985. Since their inception, these tests have undergone substantial improvements in accuracy, convenience, and speed. Still, the gold standard test for HIV diagnosis remains the enzyme-linked immunoassay (ELISA) antibody test, performed in duplicate and followed by confirmation with a Western blot [8].

Rapid HIV testing can now be performed within 20 minutes on a sample of whole blood, plasma, or oral mucosal transudate using the OraQuick Advance Rapid HIV 1/2 Antibody Test (OraSure Technologies Inc., Bethlehem, PA), which detects both HIV-1 and -2. Although this test has become one of the most commonly used point of care tests, it, like all rapid tests, remains only a screening test that requires follow-up Western blot confirmation when results are reactive [8]. Reported clusters of high false-positive rates in major US cities have demonstrated the potential for poor positive

predictive value of such screening tests in low-prevalence settings and emphasized the need to clearly label test results as preliminary [9].

Resource-limited settings

The translation of US testing kits to clinical use in resource-limited settings requires consideration of several issues. First, an appropriate test must detect HIV subtypes and clades that are prevalent in these regions. For example, while the HIV-1 group M clade B is most common in the Americas, Europe, and Australia, clade C is most common worldwide, and HIV-2 must be detectable in west Africa, where it is most prevalent [8]. The test must be heat-stable with a long shelf-life at ambient temperatures. Because most HIV testing in resource-limited settings occurs in a clinical venue, outside a standard laboratory, the test should also be easy, safe, and quick to use, as well as simple to interpret [10]. Maximizing test sensitivity is critical, because false-negative results may be of particular concern in high-prevalence settings [11–13].

The current testing strategy in most resource-limited settings is rapid tests or dual standard ELISA tests (in series or in parallel) from different manufacturers [14]. Rapid testing effectively precludes the need for confirmation with venipuncture samples and Western blot, which are often inaccessible, and saves individuals the time and cost required to retrieve test results days later. In Botswana, for example, testers begin with parallel rapid tests: UniGold Recombigen HIV (Trinity Biotech, Bray, Ireland) and Determine HIV 1/2 (Abbott Diagnostics, Abbott Park, IL). If the results of these tests are discordant, they are both repeated. If they remain discordant, the OraQuick test is used to make the final determination [15]. According to a 2004 report from the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the WHO, such combinations provide the same reliability as an ELISA supplemented with Western blot, and do so at much lower cost [10].

The high incidence of HIV in resource-limited settings and the long distances patients must often travel to access health care also mandate ready identification of acute HIV syndrome, which is not detectable by traditional antibody-based tests. New tests that detect p24 protein forming the HIV capsid are sensitive to both acute and chronic disease [16] and will soon be more widely available.

Home Testing in the United States and in Resource-Limited Settings

In the mid-1990s, some advocates promoted the availability of over-the-counter HIV tests to improve suboptimal testing rates in the United States [17]. As with home pregnancy testing, the concept of home HIV testing was motivated by consumer desire to learn one's HIV status through personal initiative in the convenience and privacy of home, and then to seek follow-up care if and when it was needed.

The first two home-collection kits were approved by the FDA in 1996, only one of which—the Home Access HIV-1 Test System (Home Access Health Corporation, Hoffman Estates, IL)—is still commercially available. Using these over-the-counter kits, clients obtain dried blood samples, send them to a laboratory for processing, and call to anonymously receive their results within a week [17,18]. Although current “home” HIV tests involve home collection of a sample that is subsequently sent out for analysis, the FDA is currently considering the over-the-counter sale of rapid tests that could be performed as well as interpreted at home [19].

Surveys on home collection kits for HIV testing in the United States demonstrated that they were highly acceptable among nearly 175,000 customers in the first year of use. Ninety-five percent of this group collected testable specimens, while 97% of them subsequently called to learn their results. Most users who responded to an associated survey were white men between 25 and 34 years old. Nearly 60% of home kit users and 49% of the 0.9% testing positive had never been tested before [18]. In another study that evaluated bimonthly testing on 241 high-risk individuals, including men who have sex with men, injecting drug users, and women at heterosexual risk, 90% to 96% of expected samples were received by the laboratory and 95% of users had test results disclosed over the telephone [20].

The FDA is currently considering the OraQuick Advance Rapid HIV 1/2 Antibody Test for over-the-counter availability and self-administration. This test has undergone an observed use study for over-the-counter use and is awaiting review by the Blood Products Advisory Committee [19,21,22]. In a survey of nearly 3000 California residents, 37% of respondents showed willingness to use an over-the-counter test [23].

In the United States, benefits of home testing include convenience, privacy, anonymity, and potentially increased access to tests [18]. Home specimen collection with telephone counseling may lead to earlier detection of disease [24]. Use of the kits has also been associated with improved outcomes: fewer high-risk behaviors in those testing positive and increased linkage to care [17,25]. In the study of bimonthly testing noted above, 98% reported their risk behaviors remained the same (77%) or became less risky (21%) as a result of testing [20]. Post-marketing analysis of the tests approved in 1996 found that 65% of those testing positive accepted referrals for care, whereas 23% of HIV-positive users already had a source of follow-up care [18].

Still, in 2009, home testing is met with controversy, in large part because it challenges the FDA's standard of linking diagnostic testing to professional counseling [21,26]. Critics also cite difficulty in conveying the implications of a positive screening test, which can lead to psychological distress, and conversely, those of a negative screening test early in infection, which can provide a false sense of security [17,26]. Some have raised concerns that this modality will not target the high-risk populations that are in greatest need

and will instead be used by groups including the affluent and the worried well. The test is currently priced at about \$40, above what most can afford or are willing to pay: survey data suggest that Americans are unwilling to spend more than \$15 on a test [17,18,22,26,27].

In resource-limited settings, home-based testing currently means door-to-door implementation of rapid tests by lay counselors or community health workers, although other approaches for distribution of self-administered tests are being considered [28]. In studies evaluating the home testing approach, counselors administer varying combinations of rapid tests that can be developed in a client's home within 20 minutes, allowing receipt of results at the same visit. Other studies evaluate the home delivery of HIV test results that have been developed in clinical settings.

Early Examples of Home Testing Success in Resource-Limited Settings

Home-based testing, part of a wider effort to identify and therefore treat more HIV-infected individuals in resource-limited settings, is showing early signs of success. Surveys and trials that assess home-based testing as well as home delivery of test results have had high test acceptability and uptake compared with facility-based testing in both urban and rural resource-limited settings, particularly among those who cannot afford the cost and time required to travel to a testing center [6,29,30]. In a randomized controlled trial of 2445 adults in urban Zambia, participants were offered testing in a clinic or an alternate location; among the latter group, 84% chose home as the venue for testing. A greater proportion of participants who were offered clinic-based testing expressed willingness to be tested, compared with those offered an alternate location (40% vs 30%). However, 56% of those willing participants in the alternate site group actually completed the testing process, compared with 12% among the clinic group. Greater initial willingness to undergo clinic-based testing may be explained by greater familiarity with this approach. The 4.7-fold overall testing completion rate of home testing was attributed in surveys to greater ease of access and privacy [5].

In a cohort study in the Rakai district of southwestern Uganda, testing completion nearly doubled from 35% in 1994 to 1995 to 65% in 1999 to 2000 with the availability of counselor-initiated home-based testing [31]. Another cohort study conducted in rural southwestern Uganda found that 1868 participants in four villages were more than five times more likely to receive results during the intervention year—in which they were offered home delivery of results obtained from annual door-to-door blood collections—compared with the year in which these results were only available in health care facilities. The confirmed receipt of test results by participants increased from 10% to 37% with the availability of home testing [29].

Another door-to-door testing program that was implemented over 2 years across the Bushenyi district of Uganda

reached 63% of all households. Population-based surveys of about 1500 adult participants conducted before and after the program found that the proportion of individuals who had ever been tested increased from 20% to 63% [32].

Further studies in countries including Uganda, Botswana, Zambia, and Mozambique have shown increased comfort level and more frequent completion of the testing process with home-based compared with clinic-based testing [33–36].

Home testing and access to specific populations

Studies suggest that home-based testing achieves its goal in reaching populations previously untapped by standard testing programs. One study in Uganda found that home-based testing by counselors most efficiently reached individuals with low rates of prior testing and those with higher CD4 counts, compared with hospital-based and other strategies [37•]. Differential rates of testing uptake and acceptance have also been shown along a number of demographic variables.

Socioeconomic status

Demographic and health surveys in sub-Saharan Africa show a strong socioeconomic gradient in the use of traditional, facility-based VCT, with lowest uptake among the poorest individuals. Home testing may be especially effective for this population [7•]. In a home-based testing campaign on Likoma Island, Malawi, members of households in the lowest income quartile were significantly less likely to have used facility-based testing and counseling services compared with the rest of the population (OR = 0.60), but more likely to use home-based services during the study (adjusted OR = 1.70) [7•]. Although sicker individuals—those frequently HIV-infected—may be expected to access health care facilities more often, the study results may be better explained by the potentially prohibitive travel and other costs required to access health care facilities, which would be particularly burdensome to this subpopulation.

Age

Studies have shown conflicting results on the age distribution of those who are tested at home. In one Ugandan study, individuals between 15 and 24 years of age were less likely to test either at home or in a clinic, when compared with other age groups [38]. Home testing may be less appealing to youth who live with their families, due to privacy issues [29]. However, a study in Zambia found highest uptake among rural males aged 15 to 19 years (3%–26%), a promising finding given that this population has been challenging to target with other testing strategies [39]. In a Mozambique study, home testing was the most effective at reaching children, compared with other community-based testing modalities [40]. Among 25- to 49-year-olds, poor self-rated health doubled the likelihood that an individual was willing to be tested at home, suggesting that ease of testing via home access would be particularly beneficial to this population [5].

Gender

Women are more likely than men to complete HIV testing in any given testing site [15,41], and in most countries, are more likely to be aware of their HIV status [42]. In studies evaluating home testing in particular, women were more likely to undergo testing than men [33,35,38,43–45]. The proportion of women who were initially offered testing was as high as 75% in urban Kenya [35]. These findings may be explained by the greater likelihood of women to remain at home during the day.

Family and partners

Home-based testing may target couples and families more efficiently than other strategies, although social considerations may complicate this benefit.

In a Mozambique study, home testing reached more couples than other community-based strategies, such as mobile testing units [40]. In kind, the home-based approach may be particularly effective at identifying household members of known HIV-infected individuals. A Ugandan study randomized 7184 household members of HIV-infected persons to be offered free home-based or clinic-based testing, counseling, and care. Reported results indicate that 56% of all HIV-infected household members in the home-testing arm were identified, compared with 27% in the clinic arm [38]. Although some studies show that couples with conflicting attitudes toward testing may be less amenable to a home visit, others suggest that for some HIV-discordant couples, home-based testing may foster family support and aid in risk reduction [6,29].

A 2007 meta-analysis by the *Cochrane Library* concluded there is still insufficient evidence to recommend large-scale implementation of the home-based testing model [6]. However, several of the more promising studies on this approach have been published since the analysis was performed; it will be important to revisit these conclusions in light of emerging data [7•,37•].

Impact on Stigma and Behavior

Fear of stigma is often cited as a major deterrent against the use of VCT centers [6,29]. Home-based testing was conceived in part to reduce the stigma associated with visiting a publicly visible, dedicated HIV testing center, by precluding this visit and normalizing the testing process. Interviews and focus groups conducted with participants report that the home-based approach has been successful not only in reducing the fear of stigmatization, but also in minimizing the emotional vulnerability associated with traditional methods [29]. In a district-wide Ugandan study, the proportion of persons willing to buy vegetables from an HIV-infected vendor increased from 74% to 83% following a 2-year home-testing program, and the proportion of persons not desiring their infected family member's serostatus to remain secret increased from 59% to 70% after this program. The proportion of persons reporting disclo-

sure of serostatus rose from 72% to 81%, suggesting increased comfort with testing outcomes [32].

Home-based testing may also be associated with fewer high-risk behaviors. In the same Ugandan study, condom use during the previous sexual act increased from 15% to 40% among HIV-infected individuals who learned their serostatus through a home testing protocol [32].

Barriers to Home Testing

Despite its increasingly recognized benefits, wide-scale implementation of counselor-initiated home-based HIV testing is not imminent due to several important barriers that may be more pronounced in resource-limited settings. These obstacles include less awareness of testing options, more difficulty acquiring these tests due to high costs and remote settings, limited availability of confirmatory tests that require serum sampling, and difficulty preserving any cold chain that may be necessary to maintain test kit viability [46].

Concern about confidentiality is an additional obstacle. Because home testing is often conducted in hard-to-reach areas, local residents are frequently employed as counselors to perform the tests. Although this approach expands testing outreach, those being tested may fear a confidentiality breach by local counselors. A few studies have addressed this concern by employing counselors from separate geographic locations [5,7•].

Some have speculated on the feasibility of self-administered home-based tests provided free of charge in resource-limited settings, similar to self-administered tests now being considered for FDA approval in the United States [19]. One potential benefit of self-testing is that it may allow overworked hospital staff members to focus on providing patients with other critical services. Some public health innovators suggest using new technologies such as mobile phone messaging to efficiently inform the public about home self-tests, as well as to improve linkage to care [47]. However, the difficulty in using and accurately interpreting tests may be a major challenge to self-administered testing. A cross-sectional study of 350 participants across two Singapore HIV testing centers found that while nearly 90% reported that the blood sample rapid test was easy to use, 85% failed to perform the steps—especially blood sampling—adequately, leading to invalid results for 56% of participants. Twelve percent were unable to correctly determine results, as confirmed by trained personnel [48]. Data have yet to be published from high HIV-prevalent regions, although extant reports suggest that self-administered testing should be approached with caution.

As with most HIV testing efforts, home self-testing without counselor involvement raises the concern of adequate consent procedures. Some argue that rapid self-tests may be more easily used without an individual's consent—particularly for women, adolescents, or the debilitated—and that physical abuse stemming from testing may be more difficult to police [49]. In developing

countries, there may also be fewer legal protections against abuse of home testing, for example by family members or employers wishing to know an individual's status without his or her consent [30].

Effect on Linkage to Care

Expanded HIV testing through modalities including home-based testing is only beneficial to individuals and to the public if testing is linked with effective prevention, medical care, and psychosocial support. Linkage of traditional VCT to these services has been a major challenge in the past, and experience suggests that testing initiatives are most efficient if linkage to care is improved, even before scale-up of testing [8,50]. Furthermore, if home testing particularly reaches populations who have difficulty accessing health care facilities, as studies have suggested, intensified outreach for linkage to clinical care will be essential for those who are identified as infected at home.

Although data on home collection for testing in the United States suggest improved linkage, studies have not adequately addressed this issue in resource-limited settings. Individuals burdened with the knowledge of a positive home test are susceptible to poor psychological outcomes, particularly if follow-up care is difficult to access. What's more, delayed initiation of ART following diagnosis is associated with high mortality rates in resource-limited settings [51]. Linkage to care is a critical reportable outcome, essential to accurate assessment of the individual benefits, costs, and impact of home testing.

Cost Effectiveness

Identification and treatment of a greater percentage of HIV-infected individuals in order to save more lives—the ultimate goal of testing scale-up—necessarily comes at a price. In a Ugandan study comparing four testing approaches, door-to-door testing was the least expensive, costing \$8.29 (2007 US dollars) per client compared with the costliest approach, stand-alone counseling and testing (\$19.26). Door-to-door testing also had the lowest ratio of cost per new client tested (\$9.21 per client). However, because home-based testing identified a much lower HIV prevalence than hospital-based testing (5.1% vs 27.2%), hospital-based testing had the lowest ratio of cost per case identified (\$43.10 vs \$163.93) [37•].

Although home-testing may be associated with a higher cost per case identified, it is important to note that a year of health-preserving ART costs about the same amount (\$130) [52]. At such costs, ART has previously been noted to be a cost-effective intervention [53]. Formal cost-effectiveness analyses are required to fully understand the economic value of home-based testing, particularly as one component of a several-pronged approach to both prevent and treat the infection.

If self-administered home testing is implemented in resource-poor settings, as some have suggested, its success is

contingent upon the affordability of the test to its consumers; ideally, the tests would be free to patients or accessible at considerably reduced cost [54]. As with the expansion of any testing effort, political will is critical to make such self-tests both feasible and effective: the introduction of self-testing kits will require collective efforts by local governments, nongovernmental organizations, the WHO, and the United Nations Education, Scientific, and Cultural Organization to ensure test affordability, availability of support services, and linkage to care [30,55].

Conclusions

HIV testing is a critical gateway to care and secondary prevention, particularly in resource-limited settings burdened with high disease prevalence. Current strategies that rely on facility-based testing have proven inadequate for the goal of universal identification and treatment over the past 10 years, demanding the use of alternate methods such as home-based testing. Home testing in resource-limited settings has met with early success, based on studies demonstrating improved access to testing, acceptability, effective case identification, behavior risk reduction, and disclosure of status, particularly among women and those of low socioeconomic status. However, the impact of this method on linkage to care, the critical last step in the testing process, remains to be seen.

Acknowledgments

This work was supported in part by the National Institute of Mental Health (R01 MH073445 and R01 MH66869), The National Institute of Allergy and Infectious Disease (K23 AI068458), and The Doris Duke Charitable Foundation, Clinical Scientist Development Award.

Disclosure

No potential conflicts of interest relevant to this article were reported.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

- Of importance
 - Of major importance
1. Joint United Nations Program on HIV/AIDS: *2006 Report on the Global AIDS Epidemic*. Geneva, Switzerland: UNAIDS; 2006. Available at http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp. Accessed August 2009.
 2. Joint United Nations Program on HIV/AIDS: *2008 Report on the Global AIDS Epidemic*. Geneva, Switzerland: UNAIDS; 2008. Available at <http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2006/default.asp>. Accessed August 2009.

3. Walensky RP, Paltiel AD, Losina E, et al.: **The survival benefits of AIDS treatment in the United States.** *J Infect Dis* 2006, **194**:11–19.
 4. Joint United Nations Program on HIV/AIDS/World Health Organization: **WHO Guidance on Provider-Initiated HIV Testing and Counselling in Health Facilities.** Available at <http://www.who.int/hiv/pub/vct/pitc2007/en/index.html>. Accessed August 2009.
 5. Fylkesnes K, Siziya S: **A randomized trial on acceptability of voluntary HIV counselling and testing.** *Trop Med Int Health* 2004, **9**:566–572.
 6. Bateganya MH, Abdulwadud OA, Kiene SM: **Home-based HIV voluntary counselling and testing in developing countries.** *Cochrane Database Syst Rev* 2007, **17**:CD006493.
 7. Helleringer S, Kohler HP, Frimpong JA, Mkandawire J: **Increasing uptake of HIV testing and counseling among the poorest in Sub-Saharan countries through home-based service provision.** *J Acquir Immune Defic Syndr* 2009, **51**:185–193.
- The 2009 study on home-based HIV testing in rural Malawi found high acceptance and success of this method, particularly among those in the lowest socioeconomic groups.
8. Wolf LL, Walensky RP: **Testing for HIV infection in the United States.** *Curr Infect Dis Rep* 2007, **9**:76–82.
 9. Branson BM, Wesolowski L, Delaney K, et al.: **Investigation of reports of excessive false-positive oral fluid rapid HIV tests [abstract 34LBb].** Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.
 10. Joint United Nations Program on HIV/AIDS/World Health Organization: **HIV Assays: Operational Characteristics (Phase I): Report 15 Antigen/Antibody ELISAs.** Available at http://www.who.int/diagnostics_laboratory/publications/en/HIV_Report15.pdf. Accessed August 2009.
 11. Bassett I, Chetty S, Giddy J, et al.: **False negative rapid HIV tests in Durban, South Africa [abstract 908].** Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.
 12. Gray RH, Makumbi F, Serwadda D, et al.: **Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study.** *BMJ* 2007, **335**:188.
 13. Aghokeng A, Dimodi H, Atem-Tambe A, et al.: **Inaccurate HIV diagnosis in developing countries: an unresolved issue [abstract 1051].** Presented at the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 8–11, 2009.
 14. Centers for Disease Control and Prevention/World Health Organization Regional Office for Africa: **Guidelines for Appropriate Evaluations of HIV Testing Technologies in Africa.** Available at <http://www.cdc.gov/dls/pdf/HIV%20Test%20Guidelines%20Africa.pdf>. Accessed August 2009.
 15. Steen TW, Seipone K, Gomez Fde L, et al.: **Two and a half years of routine HIV testing in Botswana.** *J Acquir Immune Defic Syndr* 2007, **44**:484–488.
 16. Odinsen O, Parker D, Radebe F, et al.: **Early detection of HIV-1 specific B lymphocyte derived antibodies in a high risk population.** *Clin Vaccine Immunol* 2009, **16**:1060–1065.
 17. Wright AA, Katz IT: **Home testing for HIV.** *N Engl J Med* 2006, **354**:437–440.
 18. Branson BM: **Home sample collection tests for HIV infection.** *JAMA* 1998, **280**:1699–1701.
 19. Business Wire: **OraSure Technologies Provides Update on Clinical Development Programs and OraQuick Manufacturing.** Available at http://phx.corporate-ir.net/phoenix.zhtml?c=99740&p=irol-newsArticle_Print&ID=1302191&highlight. Accessed August 2009.
 20. Spielberg F, Critchlow C, Vittinghoff E, et al.: **Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results.** HIV Early Detection Study Group. *AIDS* 2000, **14**:1819–1828.
 21. Campbell S, Klein R: **Home testing to detect human immunodeficiency virus: boon or bane?** *J Clin Microbiol* 2006, **44**:3473–3476.
 22. Spielberg F: **Over the counter HIV testing: a technology whose time has come.** Presented at the FDA Blood Products Advisory Committee Meeting. Gaithersburg, MD; November 3, 2005.
 23. Phillips KA, Chen JL: **Willingness to use instant home HIV tests: data from the California Behavioral Risk Factor Surveillance Survey.** *Am J Prev Med* 2003, **24**:340–348.
 24. Frank AP, Wandell MG, Headings MD, et al.: **Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation.** *Arch Intern Med* 1997, **157**:309–314.
 25. Marks G, Crepaz N, Senterfitt JW, Janssen RS: **Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs.** *J Acquir Immune Defic Syndr* 2005, **39**:446–453.
 26. Walensky RP, Paltiel AD: **Rapid HIV testing at home: does it solve a problem or create one?** *Ann Intern Med* 2006, **145**:459–462.
 27. Paltiel AD, Pollack HA: **Price, performance, and the FDA approval process: the example of home HIV testing.** *Med Decis Making* 2009 May 8 (Epub ahead of print).
 28. Vital Wave Consulting: **mHealth for Development: The Opportunity of Mobile Technology for Health-care in the Developing World.** Washington, DC and Berkshire, UK: United Nations Foundation-Vodafone Foundation Partnership; 2009. Available at http://www.globalproblems-globalsolutions-files.org/unf_website/assets/publications/technology/mhealth/mHealth_for_Development_full.pdf. Accessed August 2009.
 29. Wolff B, Nyanzi B, Katongole G, et al.: **Evaluation of a home-based voluntary counselling and testing intervention in rural Uganda.** *Health Policy Plan* 2005, **20**:109–116.
 30. Kachroo S: **Promoting self-testing for HIV in developing countries: potential benefits and pitfalls.** *Bull World Health Organ* 2006, **84**:999–1000.
 31. Matovu JK, Kigozi G, Nalugoda F, et al.: **The Rakai Project counselling programme experience.** *Trop Med Int Health* 2002, **7**:1064–1067.
 32. Nuwaha F, Tumwesigye E, Kasasa S, et al.: **Population-level changes in knowledge of HIV status, stigma, and HIV risk behavior after district-wide door-to-door voluntary counseling and testing: Bushenyi District, Uganda [abstract 139].** Presented at the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 8–11, 2009.
 33. Mbirizi J, Kaleeba M, Kisambira E, et al.: **Increasing access using home-based confidential HIV counseling and testing: an innovative community-based program in Uganda [abstract WEPE0364].** Presented at the XVI International AIDS Conference. Toronto, Canada; February 13–18, 2006.
 34. Kusemererwa S, Coutinho A, Kunihira A: **The effect of HBHCT on the attitude of household members towards HIV testing--TASO Mbale [abstract CDC1197].** Presented at the XVI International AIDS Conference. Toronto, Canada; February 13–18, 2006.
 35. Nawavvu C, Wanyenze R, Busingye J, et al.: **Urban home based HIV counseling and testing can improve identification of infected household members of index clients in Kampala [abstract WEAC0104].** Presented at the XVII International AIDS Conference. Mexico City, Mexico; August 3–8, 2008.
 36. Were WA, Mermin JH, Wamai N, et al.: **Undiagnosed HIV infection and couple HIV discordance among household members of HIV-infected people receiving antiretroviral therapy in Uganda.** *J Acquir Immune Defic Syndr* 2006, **43**:91–95.

37. Menzies N, Abang B, Wanyenze R, et al.: **The costs and effectiveness of four HIV counseling and testing strategies in Uganda.** *AIDS* 2009, 23:395–401.
- The cost and effectiveness analysis of home-based, hospital-based, stand-alone, and household member VCT found that while all strategies had relatively low per client costs, home-based testing had the lowest ratio of cost per new client tested, whereas hospital-based testing had the lowest ratio of cost per case identified. Home-based testing most efficiently targeted populations with low rates of prior testing. This study demonstrates the utility of a several-pronged approach to testing.
38. Lugada E, Jaffar S, Levin J, et al.: **Comparison of home- and clinic-based HIV counseling and testing among household members of persons taking ART: Uganda [abstract 138].** Presented at the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 8–11, 2009.
39. Mutale W, Michelo C, Fylkesnes K: **High uptake of home-based delivery of HIV counselling and testing among young people [abstract WEPE0366].** Presented at the XVI International AIDS Conference. Toronto, Canada; February 13–18, 2006.
40. Bossemeyer D, Cardoso J, Maranguene A, et al.: **Partnering with the community to expand integrated health counseling and testing services in Mozambique [abstract TUPE0404].** Presented at the XVII International AIDS Conference. Mexico City, Mexico; August 3–8, 2008.
41. Cockcroft A, Andersson N, Milne D, et al.: **Community views about routine HIV testing and antiretroviral treatment in Botswana: signs of progress from a cross sectional study.** *BMC Int Health Hum Rights* 2007, 7:5.
42. World Health Organization: **Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector.** Available at http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf. Accessed August 2009.
43. Kimaiyo S, Wools-Kaloustian K, Boit L, et al.: **Effectiveness and outcomes of door-to-door HIV testing in a rural district of Western Kenya [abstract TUPE0389].** Presented at the XVII International AIDS Conference. Mexico City, Mexico; August 3–8, 2008.
44. Nuwaha F, Muganzi E, Kasasa S, et al.: **District-wide, door-to-door, home-based HIV voluntary counselling and testing in rural Uganda [abstract TUAC0101].** Presented at the XVI International AIDS Conference. Toronto, Canada; August 13–18, 2006.
45. Spielberg F, Branson BM, Goldbaum GM, et al.: **Overcoming barriers to HIV testing: preferences for new strategies among clients of a needle exchange, a sexually transmitted disease clinic, and sex venues for men who have sex with men.** *J Acquir Immune Defic Syndr* 2003, 32:318–327.
46. Spielberg F, Levine RO, Weaver M: **Self-testing for HIV: a new option for HIV prevention?** *Lancet Infect Dis* 2004, 4:640–646.
47. **A doctor in your pocket: Developing countries are using mobile phones to leapfrog to personalised medicine.** *The Economist*. April 16, 2009.
48. Lee VJ, Tan SC, Earnest A, et al.: **User acceptability and feasibility of self-testing with HIV rapid tests.** *J Acquir Immune Defic Syndr* 2007, 45:449–453.
49. Merson MH, Feldman EA, Bayer R, Stryker J: **Rapid self testing for HIV infection.** *Lancet* 1997, 349:352–353.
50. Walensky RP, Weinstein MC, Smith HE, et al.: **Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral.** *Med Decis Making* 2005, 25:321–329.
51. Bassett IV, Wang B, Chetty S, et al.: **Loss to care and death before ART: patients eligible for treatment who do not make it in Durban, South Africa [abstract 839].** Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.
52. Phillips AN, Pillay D, Miners AH, et al.: **Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.** *Lancet* 2008, 371:1443–1451.
53. Goldie SJ, Yazdanpanah Y, Losina E, et al.: **Cost-effectiveness of HIV treatment in resource-poor settings--the case of Cote d'Ivoire.** *N Engl J Med* 2006, 355:1141–1153.
54. Dong K, Heywood M, Thabethe Z, Venter F: **facilitated by Grey TG: HIV testing: right to privacy or right to life.** Panel discussion at the 4th Southern African AIDS Conference. Durban, South Africa; March 31 to April 3, 2009.
55. Frerichs RR: **Harm of not permitting personal HIV screening in developing countries.** *AIDS* 1997, 11:936–937.